Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Arvinas Inc.

< Previous 1 2 Next >
Arvinas to Report Third Quarter 2025 Financial Results on November 5, 2025
From Arvinas Inc.
Via GlobeNewswire
Tickers ARVN
Arvinas Presents Preclinical Data for ARV-806 Demonstrating Robust and Differentiated Activity in Models of KRAS G12D-mutated Cancer at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
From Arvinas Inc.
Via GlobeNewswire
Tickers ARVN
Arvinas to Present Preclinical Data for ARV-806, a PROTAC KRAS G12D Degrader, at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
From Arvinas Inc.
Via GlobeNewswire
Tickers ARVN
Patient-Reported Outcomes from VERITAC-2 Clinical Trial Support Clinical Benefit of Vepdegestrant in Patients with ESR1-Mutated, ER+/HER2- Advanced or Metastatic Breast Cancer Previously Treated with Endocrine-Based Therapy
From Arvinas Inc.
Via GlobeNewswire
Tickers ARVN PFE
Arvinas to Present Data from the Vepdegestrant Clinical Development Program at the 2025 European Society for Medical Oncology (ESMO) Congress
From Arvinas Inc.
Via GlobeNewswire
Tickers ARVN
Arvinas Presents Late Breaking, Positive Phase 1 Clinical Data for ARV-102, a PROTAC LRRK2 Degrader, at the 2025 International Congress of Parkinson’s Disease and Movement Disorders®
From Arvinas Inc.
Via GlobeNewswire
Tickers ARVN
Arvinas to Present Clinical Data for ARV-102, a PROTAC LRRK2 Degrader, at the 2025 International Congress of Parkinson’s Disease and Movement Disorders®
From Arvinas Inc.
Via GlobeNewswire
Tickers ARVN
Arvinas Provides Update on Collaboration with Pfizer and Announces Further Actions to Support Value Creation
From Arvinas Inc.
Via GlobeNewswire
Tickers ARVN PFE
Arvinas to Participate in Upcoming Investor Conferences
From Arvinas Inc.
Via GlobeNewswire
Tickers ARVN
Arvinas Announces FDA Acceptance of the New Drug Application for Vepdegestrant for the Treatment of ESR1m, ER+/HER2- Advanced Breast Cancer
From Arvinas Inc.
Via GlobeNewswire
Tickers ARVN PFE
Arvinas Reports Second Quarter 2025 Financial Results and Provides Corporate Update
From Arvinas Inc.
Via GlobeNewswire
Tickers ARVN
Arvinas to Report Second Quarter 2025 Financial Results on August 6, 2025
From Arvinas Inc.
Via GlobeNewswire
Tickers ARVN
Arvinas Announces Retirement of Chief Executive Officer and Succession Plan
From Arvinas Inc.
Via GlobeNewswire
Tickers ARVN
Arvinas Presents Preclinical Data for PROTAC BCL6 Degrader, ARV-393, at the European Hematology Association 2025 Congress
From Arvinas Inc.
Via GlobeNewswire
Tickers ARVN
Arvinas Announces Submission of New Drug Application to U.S. FDA for Vepdegestrant for Patients with ESR1-Mutated ER+/HER2- Advanced or Metastatic Breast Cancer
From Arvinas Inc.
Via GlobeNewswire
Tickers ARVN PFE
Arvinas to Present Preclinical Data for PROTAC BCL6 Degrader, ARV-393, at the 2025 European Hematology Association (EHA) Annual Meeting
From Arvinas Inc.
Via GlobeNewswire
Tickers ARVN
Arvinas and Pfizer's Vepdegestrant Significantly Improves Progression-Free Survival for Patients with ESR1-Mutant, ER+/HER2- Advanced Breast Cancer
From Arvinas Inc.
Via GlobeNewswire
Tickers ARVN PFE
Arvinas to Present at Jefferies Global Healthcare Conference
From Arvinas Inc.
Via GlobeNewswire
Tickers ARVN
Arvinas Reports First Quarter 2025 Financial Results and Provides Corporate Update
From Arvinas Inc.
Via GlobeNewswire
Tickers ARVN
Arvinas to Report First Quarter 2025 Financial Results on Thursday, May 1, 2025
From Arvinas Inc.
Via GlobeNewswire
Tickers ARVN
Arvinas Shares New Preclinical Combination Data for the PROTAC BCL6 Degrader, ARV-393, at the 2025 American Association for Cancer Research Annual Meeting
From Arvinas Inc.
Via GlobeNewswire
Tickers ARVN
Arvinas Announces Results from the VERITAC-2 Trial Selected as Late-Breaking Oral Presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting
From Arvinas Inc.
Via GlobeNewswire
Tickers ARVN
Arvinas to Present Preclinical Data for PROTAC BCL6 Degrader, ARV-393, at 2025 American Association for Cancer Research® (AACR) Annual Meeting
From Arvinas Inc.
Via GlobeNewswire
Tickers ARVN
Arvinas Presents First-in-Human Data for Investigational Oral PROTAC ARV-102 Demonstrating Blood-Brain Barrier Penetration, and Central and Peripheral LRRK2 Degradation
From Arvinas Inc.
Via GlobeNewswire
Tickers ARVN
Arvinas Announces Oral Presentation at 2025 International Conference on Alzheimer’s & Parkinson’s Diseases
From Arvinas Inc.
Via GlobeNewswire
Tickers ARVN
Arvinas and Pfizer Announce Positive Topline Results from Phase 3 VERITAC-2 Clinical Trial
From Arvinas Inc.
Via GlobeNewswire
Tickers ARVN PFE
Arvinas to Participate in Upcoming Investor Conferences
From Arvinas Inc.
Via GlobeNewswire
Tickers ARVN
Arvinas Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
From Arvinas Inc.
Via GlobeNewswire
Tickers ARVN
Arvinas to Report Fourth Quarter and Full Year 2024 Financial Results on Tuesday, February 11, 2025
From Arvinas Inc.
Via GlobeNewswire
Tickers ARVN
Arvinas Updates Guidance for First- and Second-Line Phase 3 Combination Trials with Vepdegestrant, Highlights Upcoming Milestones, and Provides Corporate Update
From Arvinas Inc.
Via GlobeNewswire
Tickers ARVN
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.